Quantcast
Home > Quotes > GWPH
GWPH

GW Pharmaceuticals Plc American Depositary Shares (GWPH) Quote & Summary Data

$170.4
*  
2.29
1.36%
Get GWPH Alerts
*Delayed - data as of Mar. 20, 2019  -  Find a broker to begin trading GWPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    GWPH Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 171.88 / $ 166.7667
Share Volume
330,085
50 Day Avg. Daily Volume
519,501
Previous Close
$ 168.11
52 Week High / Low
$ 182.23 / $ 90.14
Market Cap
5,210,732,827
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
330,085
50 Day Avg. Daily Volume:
519,501

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -9.49

Trading Range

The current last sale of $170.40 is 89.04% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 171.88 $ 182.23
 Low: $ 166.7667 $ 90.14

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our proprietary cannabinoid product platform in a broad range of disease areas. In our 20 years of operations, we have established a world- leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and regulatory and manufacturing expertise. Our lead cannabinoid product is Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD), for which we retain global commercial rights. Epidiolex was approved by the FDA on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, or Dravet syndrome, in patients two years of age and older. LGS and Dravet syndrome are severe childhood-onset, drug-resistant epilepsy syndromes.  ... More ...  



Risk Grade

Where does GWPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 167.41
Open Date:
Mar. 20, 2019
Close Price:
$ 170.40
Close Date:
Mar. 20, 2019


Consensus Recommendation

Analyst Info